Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Investments: 2014-2025

Historic Long-Term Investments for Theravance Biopharma (TBPH) over the last 7 years, with Sep 2025 value amounting to $3.0 million.

  • Theravance Biopharma's Long-Term Investments was N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Theravance Biopharma's Long-Term Investments stood at $3.0 million, which was up 28.08% from $2.4 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Long-Term Investments high stood at $148.2 million for Q2 2022, and its period low was $2.3 million during Q4 2024.
  • For the 3-year period, Theravance Biopharma's Long-Term Investments averaged around $5.8 million, with its median value being $2.4 million (2025).
  • In the last 5 years, Theravance Biopharma's Long-Term Investments soared by 429.70% in 2021 and then slumped by 80.05% in 2023.
  • Over the past 5 years, Theravance Biopharma's Long-Term Investments (Quarterly) stood at $67.5 million in 2021, then spiked by 313.85% to $148.2 million in 2022, then plummeted by 80.05% to $18.8 million in 2023, then reached $2.3 million in 2024, then reached $3.0 million in 2025.
  • Its Long-Term Investments stands at $3.0 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.3 million for Q1 2025.